Actively Recruiting
Decoupling Immunotherapy Toxicity and Cancer Response
Led by M.D. Anderson Cancer Center · Updated on 2026-02-03
1200
Participants Needed
1
Research Sites
233 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
CONDITIONS
Official Title
Decoupling Immunotherapy Toxicity and Cancer Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6 18 years
- Plan to start immune checkpoint inhibitor for cancer therapy
You will not qualify if you...
- No baseline blood collection prior to initiation
- Not considered a good candidate for evaluation of outcome events by the principal investigator at time of evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
N
Nicolas Palaskas, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here